Alzheimer Disease

Roskamp Institute researchers discover new class of drugs that can impact Alzheimer disease

Published in Genetics and Environmental Business Week, February 22nd, 2007

The Roskamp Institute announced the discovery of a new class of drugs that lower the production of the main pathological protein that causes Alzheimer disease. The discovery is detailed in an article co-authored by doctors Daniel Paris and Michael Mullan and currently appears in Neuroscience Letters.

The Roskamp Institute, which is devoted to finding treatments for Alzheimer disease, has been researching drugs that have the potential to stop the production of B-amyloid.

"When B-amyloid builds up in humans, patients develop Alzheimer's disease," said Mullan, director of the Roskamp Institute. "By stopping its production we can potentially stop...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week

Source: Genetics and Environmental Business Week (2007-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry